

## **REMARKS**

Upon entry of the foregoing amendments, claims 1-7, 10-11, 13-15 and 18 will be pending in the present patent application. Claims 11, 12 and 16-18 are rejected. Claims 1-10 and 13-15 are objected to. In view of the foregoing amendments and the following remarks, reconsideration and withdrawal of the present basis for rejecting and objecting to the claims herein of this application are respectfully requested.

### **I. Discussion of the Amendment**

Claims 1-7 and 10 are amended to limit the scope thereof to the elected subject matter as defined by the Examiner.

Claim 11 is amended to delete the term “derivatives” and the phrase “functional groups can also be present that are subsequently transformed into final groups present in...” and similar phrases that are deemed indefinite by the Examiner, and replace the phrase “can be” with “is”.

Claim 18 is amended to limit to the use of the compound of claim 1 to treating thrombosis.

Claims 8-9, 12 and 16-17 are canceled, without prejudice.

Applicants reserve the right to pursue the cancelled or deleted subject matter in a subsequent application.

Applicants submit that this amendment does not add any new matter.

### **II. Discussion of the Rejection Under 35 U.S.C. 112, First Paragraph**

Claims 16-18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.

Applicants submit that claim 18 has been amended to limit to the use of the compound of claim 1 to treating thrombosis, which is noted as allowable by the Examiner. Furthermore, claims 16-17 have been canceled, without prejudice. Thus, the foregoing amendment has obviated the instant rejection. Accordingly, Applicants respectfully request reconsideration and withdrawal of the instant rejection on claims 16-18.

### **III. Discussion of the Rejection Under 35 U.S.C. 112, Second Paragraph**

Claims 11-12, 16-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regard as the invention.

Applicants submit that claim 11 has been amended to delete the term “derivatives”, and the phrase “functional groups can also be present that are subsequently transformed into final groups present in...” and similar phrases that are deemed indefinite by the Examiner, and replace the phrase “can be” with “is”. In addition, claim 18 has been amended to limit to the use of the compound of claim 1 to treating thrombosis, which is noted as allowable by the Examiner. Furthermore, claims 12 and 16-17

have been canceled, without prejudice. Thus, the forgoing amendment has obviated the instant rejection. Accordingly, Applicants respectfully request reconsideration and withdrawal of the instant rejection on claims 11-12 and 16-18.

**IV. Discussion of the Objection**

Claims 1-10, 13-15 are objected to for containing non-elected subject matter.

Applicants submit that claims 1-7 and 10 have been amended to limit the scope thereof to the elected subject matter as defined by the Examiner. Furthermore, claims 8-9 have been canceled, without prejudice. Thus, the forgoing amendment has obviated the instant rejection. Accordingly, Applicants respectfully request reconsideration and withdrawal of the instant rejection on claims 1-10, as well as on claims 13-15 by virtue of their dependency on claim 1.

**V. Priority Document**

The Examiner state that "[t]he foreign priority document in application 10/728,339 is EP 03011307.0, 5/19/03, not 03011303.9." (See the Action, page 4).

Applicants fail to understand the purpose of the Examiner's comment on the foreign priority document of application 10/728,339, which is not the present application 10/849,088. Applicants submit that the foreign priority document of the present application 10/849,088 is EP 03011303.9, as cited in the Declaration and the filing receipt. Applicants respectfully request clarification on this issue.

**VI. Conclusion**

Applicants respectfully submit that this application is now in condition for allowance. Accordingly, an indication of allowability and an early Notice of Allowance are respectfully requested. If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-3582.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065  
Attorney for Applicants

Date: July 24, 2007

sanofi-aventis U.S. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626

Aventis Docket No. DEAV2003-0032 US NP